Tesamorelin cost:
$150 to $3,000+ per month, depending on source.

Pharmaceutical-grade tesamorelin — the FDA-approved finished product used in Phase III trials and available through licensed pharmacies on prescription — is among the most expensive peptide therapies on the market. Historical retail pricing has run approximately $3,000 to $4,500 per month for the daily 2 mg dose, with specific cash prices varying by pharmacy, geography, and year.

This high tesamorelin cost reflects several factors. The manufacturer holds market exclusivity for the approved indication. The indication itself — HIV-associated lipodystrophy — is a small patient population, so the per-patient pricing must amortize development and manufacturing costs across fewer units. Production requires full pharmaceutical GMP standards with batch-level testing for purity, potency, and sterility that substantially exceeds compounded or research-grade manufacturing. These costs are real and contribute to the price, though reasonable observers disagree on whether the final retail tesamorelin price is justified by them.

A full 26-week protocol at pharmaceutical pricing costs approximately $18,000 to $27,000 cash. A 52-week protocol roughly doubles that. These numbers are largely prohibitive for cash-pay patients outside the FDA-approved indication, which is why almost no off-label tesamorelin use happens through the pharmaceutical channel — the compounding pharmacy and research channels absorb the off-label market.

Compounding pharmacies produce tesamorelin under the framework that allows prescription compounding of non-available or individualized drug preparations. Tesamorelin compounded through licensed 503A or 503B compounding pharmacies is legally available with a prescription from a licensed provider, typically through telehealth peptide therapy clinics that connect patients with prescribers and partnered compounding pharmacies.

Compounded tesamorelin cost typically runs $500 to $1,500 per month at the standard 2 mg daily dose, depending on the specific compounding pharmacy, the vial configuration (2 mg, 5 mg, or 10 mg vials), and any markup by the prescribing telehealth clinic. Many clinics bundle the monthly tesamorelin cost with provider consultation fees, lab testing, and ongoing clinical supervision, so the all-in cost structure matters more than the raw tesamorelin price per vial.

Compounded tesamorelin is manufactured to pharmaceutical compounding standards but does not go through the same FDA review process as the approved pharmaceutical product. Quality can vary between compounding pharmacies — reputable 503B compounders produce product with purity and sterility testing similar to pharmaceutical grade, while less reputable 503A pharmacies may produce product with less rigorous quality control. Patients using compounded tesamorelin should verify the compounder's accreditation, request certificates of analysis when available, and use telehealth clinics partnered with established 503B facilities.

A full 26-week protocol at compounding pharmacy pricing runs approximately $3,000 to $9,000 — substantially less than pharmaceutical cost but meaningfully more than research channels. This tier is where most legitimate off-label tesamorelin use happens, particularly for body composition, NAFLD, and age-related GH decline applications outside the HIV indication.

Research-grade tesamorelin is sold through research peptide suppliers for laboratory use only — not intended for human consumption and not reviewed by the FDA for human safety. Pricing at this tier runs approximately $150 to $400 per month for equivalent dosing, depending on the supplier, vial configuration, and purity grade.

The research-grade price is dramatically lower than pharmaceutical or compounded tesamorelin for several reasons. Research-grade suppliers do not operate under pharmaceutical GMP standards — they produce peptide at research-grade purity without the rigorous batch testing, sterility validation, and regulatory oversight of pharmaceutical manufacturing. The legal framework under which research peptide is sold (for laboratory use only, not for human consumption) reduces compliance costs substantially. And the research-peptide market is more competitive, with many suppliers pricing aggressively to compete for researcher and off-label customer share.

The tradeoffs are real. Research-grade tesamorelin has not been reviewed by the FDA for purity, potency, or contaminants. Quality varies significantly between suppliers — reputable research peptide vendors post third-party certificates of analysis confirming peptide identity and purity above 95-99%, while less reputable suppliers may provide product with substantially lower purity, misidentified peptides, or bacterial contamination from inadequate sterility protocols. Research-grade tesamorelin is not prescribed and not supervised, so any user is assuming all clinical, safety, and quality risk personally.

A full 26-week protocol at research-grade pricing runs approximately $900 to $2,400 — within reach of most cash-pay users who are willing to assume the additional regulatory and quality risk. This is the tier where most self-directed off-label use happens and is the most common tesamorelin source in the research peptide and biohacking communities.

Recent enforcement actions in the research peptide industry — including the shutdown of major suppliers in 2025 and 2026 — have reduced availability and increased caution among users of this channel. Patients considering research-grade tesamorelin should research the supplier's history, verify current availability, and understand that the entire channel faces regulatory uncertainty.

Insurance coverage for pharmaceutical tesamorelin exists but is narrow. Coverage is most reliable for patients meeting the FDA-approved indication: HIV-associated lipodystrophy confirmed by clinical diagnosis, imaging evidence of excess abdominal fat, and documented medical necessity for pharmacologic intervention. Even within this population, prior authorization is typically required, step therapy criteria may apply, and patient cost-sharing (copays, coinsurance, deductibles) can still be substantial.

Off-label tesamorelin — prescribed for non-HIV populations, NAFLD outside HIV, body composition, or anti-aging — is typically not covered by insurance. Prior authorization requests for off-label use are almost universally denied. Patients seeking tesamorelin for these indications should expect to pay cash through either pharmaceutical retail (expensive), compounding pharmacy (moderate), or research-grade channels (cheap).

Medicare Part D coverage for pharmaceutical tesamorelin follows the same pattern as commercial insurance — coverage for on-label indication subject to prior authorization, typically not covered for off-label use. Patient assistance programs through the manufacturer have historically provided cost reduction for eligible HIV patients facing coverage gaps. Patients with HSA or FSA accounts can sometimes use those funds for prescribed tesamorelin costs; compounded tesamorelin may be reimbursable under some plans, while research-grade tesamorelin never is.

For patients whose primary barrier is insurance coverage, the practical options are: (1) pursue pharmaceutical tesamorelin with insurance for on-label HIV indication, (2) pay cash through a compounding pharmacy/telehealth clinic for off-label use, or (3) accept the regulatory tradeoffs of research-grade channels. Each path serves different patient profiles and financial constraints.

The Phase III clinical trials used a 26-week protocol at 2 mg daily, so "one full protocol" is a useful cost benchmark. The math at each tier:

The numbers above are tesamorelin-only and do not include additional protocol costs. A complete protocol typically adds:

Clinical oversight. Physician consultation, lab testing (IGF-1 at baseline, 4 weeks, and 12+ weeks), and ongoing clinical supervision. Through a telehealth peptide clinic, this typically adds $300–800 to the initial setup and $100–300 per follow-up visit. For self-directed research-grade use, there is no clinical oversight cost but also no clinical support.

Bacteriostatic water and syringes. Needed for reconstitution and injection. Typically $30–60 for a 6-month supply of bacteriostatic water and $20–40 for insulin syringes. Minor additions to total cost but required for any tier.

Stack add-ons. Many patients use tesamorelin with ipamorelin or other peptides. A tesamorelin ipamorelin stack adds the cost of ipamorelin, which is typically $100–300/month at compounded or research-grade pricing.

Body composition tracking. DEXA scans at baseline and 26 weeks to document VAT reduction cost approximately $100–300 each. Not required but useful for confirming response. InBody or similar bioimpedance tracking is cheaper and available at many gyms.

Access to each tesamorelin tier varies geographically. Pharmaceutical tesamorelin is available by prescription at retail pharmacies nationwide in the US but specifically stocked by larger specialty pharmacies rather than neighborhood chains — most cash-pay or insurance prescriptions route through a specialty pharmacy that ships to the patient. Major HIV-care specialty pharmacies typically carry tesamorelin consistently; general retail pharmacies may need to special-order it.

Compounding pharmacy tesamorelin is available through telehealth platforms that operate in most US states. Some states restrict peptide compounding more than others — notably California, where recent state-level regulation has added restrictions on certain compounded peptides. Patients in more restrictive jurisdictions may find fewer telehealth options or longer consultation processes, though most states allow compounded tesamorelin with a valid prescription.

Research-grade tesamorelin is available through research peptide suppliers operating online, with products typically shipped in refrigerated or non-refrigerated packaging to US addresses. Geographic restrictions are minimal at this tier since the suppliers are selling for research use only and not practicing medicine, though some suppliers restrict shipping to certain jurisdictions for various compliance reasons.

For patients seeking "tesamorelin near me" in the sense of in-person clinical care, options depend on HIV indication status. Patients with HIV-associated lipodystrophy can access tesamorelin through their HIV clinic or endocrinologist. Patients pursuing off-label tesamorelin typically work with telehealth peptide therapy providers that operate by video consultation nationwide rather than with local in-person clinics, since the specialized knowledge needed is concentrated in a relatively small number of peptide-focused clinicians.

Tesamorelin's pricing is at the high end of the peptide therapy spectrum, particularly at pharmaceutical grade. Rough comparison to other commonly used peptides at compounded or research-grade pricing:

Tesamorelin. $150–1,500/mo depending on tier. Most expensive in the GH-axis peptide category.

Sermorelin. $75–400/mo compounded. Substantially cheaper than tesamorelin due to both lower peptide cost and smaller doses per daily injection. See the tesamorelin vs sermorelin guide for the efficacy tradeoff.

Ipamorelin. $100–300/mo. A small peptide at modest doses, and widely available through compounding pharmacies and research channels.

CJC-1295. $100–350/mo for the non-DAC version, slightly higher for the DAC version.

BPC-157. $75–250/mo at typical doses. A different class of peptide (systemic healing/regenerative rather than GH-axis) but worth mentioning for cost context. See the BPC-157 peptide guide.

Semaglutide. Highly variable — $100–200/mo at research grade, $300–800/mo compounded, and $900–1,400/mo pharmaceutical. Different clinical goal (weight loss vs VAT-specific reduction) than tesamorelin. See the semaglutide peptide guide.

The tesamorelin price premium over alternatives reflects its clinical evidence base (Phase III data that most other peptides lack), FDA approval status, and pharmacologic efficacy (the larger GH pulse and stronger VAT reduction). Whether the premium is worth it depends on what specific outcome is being targeted and how much clinical evidence matters to the decision.